Free Trial
NASDAQ:FNCH

Finch Therapeutics Group (FNCH) Stock Price, News & Analysis

Finch Therapeutics Group logo
$12.70 +0.10 (+0.79%)
As of 11:10 AM Eastern

About Finch Therapeutics Group Stock (NASDAQ:FNCH)

Key Stats

Today's Range
$12.02
$12.70
50-Day Range
$12.00
$13.48
52-Week Range
$10.15
$15.85
Volume
631 shs
Average Volume
2,173 shs
Market Capitalization
$20.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Finch Therapeutics Group Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
10th Percentile Overall Score

FNCH MarketRank™: 

Finch Therapeutics Group scored higher than 10% of companies evaluated by MarketBeat, and ranked 902nd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Finch Therapeutics Group.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Finch Therapeutics Group is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Finch Therapeutics Group is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Finch Therapeutics Group has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.03% of the outstanding shares of Finch Therapeutics Group have been sold short.
  • Short Interest Ratio / Days to Cover

    Finch Therapeutics Group has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Finch Therapeutics Group has recently increased by 400.00%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Finch Therapeutics Group does not currently pay a dividend.

  • Dividend Growth

    Finch Therapeutics Group does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.03% of the outstanding shares of Finch Therapeutics Group have been sold short.
  • Short Interest Ratio / Days to Cover

    Finch Therapeutics Group has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Finch Therapeutics Group has recently increased by 400.00%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Finch Therapeutics Group has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Finch Therapeutics Group this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Finch Therapeutics Group insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    44.90% of the stock of Finch Therapeutics Group is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 21.77% of the stock of Finch Therapeutics Group is held by institutions.

  • Read more about Finch Therapeutics Group's insider trading history.
Receive FNCH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Finch Therapeutics Group and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

FNCH Stock News Headlines

Free: The Crypto Summit That Could Change Your Life
27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your spot for FREE.tc pixel
FNCH Finch Therapeutics Group, Inc. - Seeking Alpha
Arquitos Capital's Largest Holdings For Q1 2025
Arquitos Capital Management Q4 2024 Commentary
Finch Therapeutics announces Nasdaq delisting, SEC deregistration
See More Headlines

FNCH Stock Analysis - Frequently Asked Questions

Finch Therapeutics Group's stock was trading at $11.30 on January 1st, 2025. Since then, FNCH shares have increased by 6.5% and is now trading at $12.03.

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) released its earnings results on Wednesday, November, 10th. The company reported ($6.30) earnings per share for the quarter, topping analysts' consensus estimates of ($12.60) by $6.30. The company had revenue of $11.34 million for the quarter.

Finch Therapeutics Group's stock reverse split on the morning of Monday, June 12th 2023.The 1-30 reverse split was announced on Monday, June 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Finch Therapeutics Group (FNCH) raised $101 million in an initial public offering (IPO) on Friday, March 19th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI acted as the underwriters for the IPO.

Shares of FNCH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Finch Therapeutics Group investors own include CNS Pharmaceuticals (CNSP), Faraday Future Intelligent Electric (FFIE), Allarity Therapeutics (ALLR), Aridis Pharmaceuticals (ARDS), Meta Platforms (META), NVIDIA (NVDA) and Altamira Therapeutics (CYTO).

Company Calendar

Last Earnings
11/10/2021
Today
9/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:FNCH
CIK
1733257
Fax
N/A
Employees
190
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($8.82)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$74.75 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-69.14%
Return on Assets
-26.92%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.87
Quick Ratio
3.87

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$14.25 per share
Price / Book
0.84

Miscellaneous

Outstanding Shares
1,606,000
Free Float
885,000
Market Cap
$19.32 million
Optionable
No Data
Beta
1.19
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:FNCH) was last updated on 9/4/2025 by MarketBeat.com Staff
From Our Partners